Kalaris Therapeutics, Inc. (KLRS)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q1-2026 | 8-K (2026-05-12) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-03-17) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-12) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-13) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-14) · 99.1 | 8-K (2025-03-18) · 99.1 · 99.2 · 99.3 · 99.4 | ||
| 10-K | FY-2024 | — | ||
| 10-Q | Q3-2024 | — | ||
| 10-Q | Q2-2024 | — | ||
| 10-Q | Q1-2024 | — | ||
| 10-K | FY-2023 | — | ||
| 10-Q | Q3-2023 | 8-K (2023-11-02) · 99.1 | ||
| 10-Q | Q2-2023 | 8-K (2023-08-03) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Document and Entity Information | ||
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Condensed Consolidated Statements of Operations (unaudited) | — |
|
| Condensed Statements of Operations and Comprehensive Loss | — |
|
| Consolidated Statements of Operations and Comprehensive Loss | ||
| Condensed Consolidated Statements of Operations (unaudited) (P) | — |
|
| Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) (P) | — |
|
| Condensed Statements of Operations and Comprehensive Loss (P) | — |
|
| Consolidated Statements of Changes In Stockholders' Equity | ||
| Consolidated Statements of Changes In Stockholders' Equity (P) | ||
| Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (deficit) | ||
| Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (deficit) (P) | ||
| Consolidated Statements of Cash Flows | ||
| Consolidated Statements of Cash Flows (P) | ||
| Notes | ||
| Accrued Expenses | ||
| Balance Sheet Components | ||
| Commitments and Contingencies | ||
| Common Stock | — |
|
| Convertible Promissory Notes | ||
| Cybersecurity Risk Management, Strategy and Governance | — |
|
| Defined Contribution Plan | ||
| Description of Business, Organization and Liquidity | — |
|
| Employee Benefit Plans | — |
|
| Fair Value Measurements | ||
| Fair Value Measurements and Fair Value of Financial Instruments | — |
|
| Income Taxes | ||
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Leases | ||
| Marketable Securities | — |
|
| Merger With Allovir | ||
| Nature of The Business | ||
| Net Loss Per Share | ||
| Net Loss Per Share Attributable To Common Stockholders | ||
| Pay Vs Performance Disclosure | ||
| Property and Equipment, Net | — |
|
| Redeemable Convertible Preferred Stock | ||
| Related Parties | ||
| Related Party Transactions | ||
| Restructuring Costs | ||
| Segment Reporting | ||
| Short-term Investments | ||
| Short-term Marketable Securities | — |
|
| Significant Agreements | ||
| Sponsored Research, Collaboration and License Agreements | — |
|
| Stock Option Plan and Stock-based Compensation | — |
|
| Stock-based Compensation | ||
| Stockholder's Equity | ||
| Stockholders' Equity (deficit) | ||
| Subsequent Events | ||
| Summary of Significant Accounting Policies | ||